Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.

Youjin OhSung Mi YoonJeeyeon LeeJoo Hee ParkSoowon LeeTimothy HongLiam Il-Young ChungSumedha SudhamanTimothy RiddellCharuta C PalsuledesaiMichael KrainockMinetta C LiuYoung Kwang Chae

Published in: Thoracic cancer (2024)

Our real-world data indicate that longitudinal, personalized, tumor-informed ctDNA monitoring is a valuable tool in patients with NSCLC receiving curative treatment to identify patients at high risk for recurrence.

Keyphrases

circulating tumor
cell free
prognostic factors
circulating tumor cells
end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
rectal cancer
high throughput
electronic health record
free survival
big data
single molecule
brain metastases
smoking cessation